MetaCap

Alaunos Therapeutics (TCRT) vs Vistagen Therapeutics (VTGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vistagen Therapeutics is the larger company by market cap ($7.6 million vs $7.0 million), about 1.1 times the size. Vistagen Therapeutics converts more of its revenue into profit, with a net margin of -5491.3% versus -83520.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TCRT+98.07%VTGN-33.79%
+289%+120%-49%
Oct 7, 20261 yearNov 20, 2026
TCRT+111.25%VTGN-30.71%
+248%+102%-44%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TCRT versus VTGN key metrics
MetricTCRTVTGN
Share price$1.66$0.1636
Market cap$6.99M$7.56M
1-day change+3.75%-12.33%
YTD return—-75.21%
1-year return—-96.44%
5-year return—-99.72%
EPS (TTM)$-1.76$-1.36
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$5.00K$1.27M
Revenue growth (YoY)-50.00%+161.11%
Net income (latest FY)$-4.18M$-69.69M
Operating margin-84500.00%-5683.69%
Net margin-83520.00%-5491.33%
52-week high$4.50$5.14
52-week low$0.72$0.16
Distance from 52-week high-63.11%-96.82%
Analyst consensus—none
Avg. price target upside—+511.25%
Average volume7.56M10.30M
Shares outstanding4.21M46.19M
Employees141
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Vistagen Therapeutics is more profitable, keeping -5491.3 cents of every revenue dollar as net income versus -83520.0 cents for Alaunos Therapeutics.
  • Vistagen Therapeutics grew revenue faster in its latest fiscal year (+161.11% vs -50.00%).

About Alaunos Therapeutics

TCRT stock →

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

About Vistagen Therapeutics

VTGN stock →

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees

TCRT vs VTGN FAQ

Which is bigger, Alaunos Therapeutics or Vistagen Therapeutics?

Vistagen Therapeutics (VTGN) is larger, with a market capitalization of $7.56M compared with $6.99M for Alaunos Therapeutics (TCRT).

Are Alaunos Therapeutics and Vistagen Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons